 Gilead Sciences Inc. won U.S. approval Friday to begin selling the first pill that promises to cure most hepatitis C patients without requiring other medicines, but its near $100,000 cost will likely further inflame tensions between drug companies and health insurers over spiraling prices.. The drug, dubbed Harvoni, builds on Gileadâ€™s blockbuster Sovaldi treatment, which recorded the biggest drug launch in history after going on sale late last year and is itself a lightning rod for critics of drug prices. 